high mobility group box 1 pseudogene 28Genealiases: []
Q-omics provides the consensus-scored HMGB1P28 profile across patient tissues and cancer cell-line models. HMGB1P28 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HMGB1P28 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, HMGB1P28 RNA expression shows 6,527 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, THCA, and STAD as cancer lineages where HMGB1P28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P28 survival associations across molecular data types. HMGB1P28 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P28 RNA expression–survival associations across cancer types. High HMGB1P28 expression shows unfavorable associations in KIRC, STAD, DLBC and ACC, but favorable associations in BLCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HMGB1P28 RNA expression.
This table summarizes HMGB1P28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P28 shows lower tumor expression in THCA and higher tumor expression in BRCA. The THCA box plot shows higher HMGB1P28 RNA expression in normal versus tumor tissue (log2 FC = −0.120, t-test p = .010).
This table shows molecular features associated with HMGB1P28 in patient tissues and cancer cell lines. In patient samples, HMGB1P28 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
